Common Equity: The sum of all common equity items.
Neurocrine Biosciences, Inc. (NBIX) had Common Equity of $3.25B for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.86B |
|
$478.60M |
|
$52.10M |
|
$2.81B |
|
$2.24B |
|
$619.10M |
|
$86.30M |
|
$705.40M |
|
$709.40M |
|
$478.60M |
|
$478.60M |
|
$478.60M |
|
$483.89M |
|
$619.10M |
|
$636.50M |
|
99.50M |
|
102.50M |
|
$4.81 |
|
$4.67 |
|
| Balance Sheet Financials | |
$2.52B |
|
$89.80M |
|
$2.11B |
|
$4.63B |
|
$743.40M |
|
-- |
|
$635.00M |
|
$1.38B |
|
|
Common Equity |
$3.25B |
$3.25B |
|
$3.25B |
|
100.10M |
|
| Cash Flow Statement Financials | |
$782.70M |
|
$-264.40M |
|
$-38.30M |
|
$241.00M |
|
$721.00M |
|
$480.00M |
|
$217.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
98.18% |
|
21.64% |
|
21.64% |
|
22.25% |
|
24.66% |
|
16.73% |
|
$748.70M |
|
-- |
|
-- |
|
-- |
|
0.62 |
|
0.76 |
|
4.17 |
|
87.64 |
|
14.71% |
|
14.71% |
|
10.33% |
|
14.71% |
|
$32.50 |
|
$7.30 |
|
$7.64 |
|